As precision oncology enters a new phase of maturity, the industry is confronting a critical reality: genomic insight alone is not always enough to predict therapeutic success. While molecular profiling has become a cornerstone of cancer care, variability in drug response continues to challenge clinicians and health systems alike. An evolving, alternative and viable solution is functional precision oncology: an approach that tests therapies directly on living patient-derived tumour material to generate actionable, patient-specific evidence of drug efficacy.

To gain greater insight, we sat down with Jens Kelm, Co-Founder of PreComb, who provides valuable insight into the clinical rationale behind functional profiling and how automation and platform integration are opening new pathways to improved patient outcomes and health-system integration.
Functional precision oncology has gained significant attention in recent years. Why is it so important to complement molecular profiling with functional testing?
Molecular profiling has transformed oncology by helping us understand the genetic landscape of tumours. However, genetics alone does not always predict how a patient’s cancer will actually respond to a specific therapy. Tumours are biologically complex, dynamic systems. Two patients with similar molecular profiles can respond very differently to the same treatment.
Functional precision oncology addresses this gap by directly testing living tumour material against therapeutic agents. Instead of inferring response from genomic alterations, we measure drug efficacy in real time using the patient’s own tumour cells. This provides a patient-specific assessment of therapeutic effectiveness, offering a powerful complement to molecular data and significantly improving the likelihood of selecting the right therapy.
How does the PreComb platform translate this concept into a clinically usable solution?
Our goal from the outset was to move functional testing from an experimental, research-focused activity into a standardised, clinically deployable system. The PreComb platform is designed as a fully integrated, end-to-end workflow — from fresh tumour material to data-driven clinical decision support.
Importantly, we go beyond static viability measurements. Instead of a single endpoint, we generate dynamic, time-resolved drug response profiles under physiologically relevant conditions. This gives clinicians deeper insight into response strength, durability, and kinetics — factors that are highly relevant in real-world therapeutic decision-making.
By embedding the entire process in a highly automated and standardised architecture, we ensure that functional testing can be performed routinely in clinical laboratories, not just in specialised centres.
A key differentiator of PreComb is its decentralised deployment model. Why is that so critical?
Functional testing depends on fresh, viable tumour material, so time is always a constraint. But the bigger issue isn’t just logistics, it’s integration.
If precision oncology is to move beyond academic pilot projects and become routine clinical practice, hospitals cannot be treated merely as sample providers. Clinical partners must be embedded in the value chain. They need ownership of the process, operational involvement, and the ability to integrate testing seamlessly into their workflows.
A purely centralised model creates bottlenecks, operationally, logistically, and strategically. It limits scalability because it keeps expertise, infrastructure, and decision-making concentrated in a few locations.
Our decentralised deployment model brings the screening platform directly to hospital sites. This allows functional drug testing to be performed immediately after tissue acquisition, but just as importantly, it positions clinical partners as active participants rather than passive senders of material.
By enabling hospitals to run highly automated, standardised 3D functional assays locally, we create a distributed network rather than a central hub. That network effect is what ultimately enables scalability across institutions and healthcare systems.
Only through decentralisation can this approach move from specialised innovation to broad clinical adoption.
Can you describe the core technology behind the platform?
At the heart of PreComb is an automated 3D functional screening system. After standardised tissue processing, tumour cells are automatically seeded into 384-well plates. Within three to five days, they self-organise into three-dimensional tumour microtissues, typically around 300 micrometres in diameter.
These microtissues preserve the cellular composition and functional heterogeneity of the original tumour, providing a physiologically relevant model for drug testing. Because we use miniaturised, parallelised formats, we can perform high-content screening while minimising the amount of patient material required — which is crucial in a clinical context.
Drug exposure and response monitoring extend over up to two weeks. This time-resolved analysis enables us to generate dynamic response profiles rather than relying on a single snapshot. Importantly, we translate these functional readouts into clinically meaningful categories aligned with established response frameworks such as RECIST. That makes the data directly interpretable within existing therapeutic decision pathways.
What impact does automation have on access and scalability?
Automation is the key enabler. Functional oncology assays are inherently complex. Without automation and standardisation, they remain labour-intensive and difficult to scale.
By embedding the assays into a platform-based architecture, we significantly lower technical and operational barriers. Hospitals do not need bespoke infrastructure or highly specialised, research-driven workflows. Instead, they can deploy a standardised system designed for routine clinical use.
This shift — from handcrafted experimentation to industrialised platform deployment — unlocks substantial market potential. It allows functional precision oncology to move beyond individual centres of excellence and into broader clinical practice, where it can benefit many more patients.
What role can the Tecan Veya® platform play in this evolution?
Industrial automation platforms like the Tecan Veya® platform are instrumental in accelerating clinical adoption. Veya® provides a proven, high-performance foundation for reproducibility, regulatory alignment, and multi-site roll-out.
By leveraging such an established automation backbone, we enhance system robustness and ensure consistent execution across decentralised sites. It supports standardised workflows, quality control, and traceability — all critical for integration into regulated clinical environments.
In essence, combining our functional oncology expertise with the industrial strength of the Tecan Veya® platform transforms functional drug testing into a deployable medtech solution. It creates the infrastructure necessary for health-system integration and sustainable commercialisation.
Looking ahead, how do you see functional precision oncology shaping patient outcomes?
We believe functional precision oncology will become a routine component of therapeutic decision-making. As cancer therapies become more numerous and complex, selecting the optimal treatment for each individual patient becomes increasingly challenging.
By directly measuring drug response in patient-derived tumour models, we provide actionable, patient-specific data that can reduce trial-and-error treatment selection. This has the potential to improve response rates, avoid ineffective therapies, and ultimately enhance both clinical outcomes and quality of life.
Our vision is to position functional precision oncology not as a niche innovation, but as a scalable, accessible technology that meaningfully impacts therapeutic decision-making for a large and growing patient population. Through automation, standardisation, and platforms like Tecan Veya®, we are making that vision achievable.